PL377209A1 - Leczenie nowotworów poprzez podawanie pacjentom częściowo dojrzałych in vitro komórek dendrytycznych - Google Patents

Leczenie nowotworów poprzez podawanie pacjentom częściowo dojrzałych in vitro komórek dendrytycznych

Info

Publication number
PL377209A1
PL377209A1 PL377209A PL37720903A PL377209A1 PL 377209 A1 PL377209 A1 PL 377209A1 PL 377209 A PL377209 A PL 377209A PL 37720903 A PL37720903 A PL 37720903A PL 377209 A1 PL377209 A1 PL 377209A1
Authority
PL
Poland
Prior art keywords
dendritic cells
tumor
cells
partially matured
administration
Prior art date
Application number
PL377209A
Other languages
English (en)
Inventor
Marnix L. Bosch
Original Assignee
Northwest Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics, Inc. filed Critical Northwest Biotherapeutics, Inc.
Publication of PL377209A1 publication Critical patent/PL377209A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL377209A 2002-12-06 2003-12-05 Leczenie nowotworów poprzez podawanie pacjentom częściowo dojrzałych in vitro komórek dendrytycznych PL377209A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43126702P 2002-12-06 2002-12-06

Publications (1)

Publication Number Publication Date
PL377209A1 true PL377209A1 (pl) 2006-01-23

Family

ID=32507696

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377209A PL377209A1 (pl) 2002-12-06 2003-12-05 Leczenie nowotworów poprzez podawanie pacjentom częściowo dojrzałych in vitro komórek dendrytycznych

Country Status (19)

Country Link
US (2) US20060057120A1 (pl)
EP (2) EP2260861A1 (pl)
JP (2) JP4859169B2 (pl)
KR (1) KR101144196B1 (pl)
CN (2) CN1738619B (pl)
AT (1) ATE486125T1 (pl)
AU (2) AU2003293411B2 (pl)
BR (1) BRPI0317064B8 (pl)
CA (1) CA2509058A1 (pl)
DE (1) DE60334725D1 (pl)
DK (1) DK1567155T3 (pl)
ES (1) ES2354944T3 (pl)
HK (1) HK1082180A1 (pl)
IL (1) IL169002A (pl)
MX (1) MXPA05006042A (pl)
PL (1) PL377209A1 (pl)
PT (1) PT1567155E (pl)
RU (1) RU2348418C2 (pl)
WO (1) WO2004053072A2 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2348418C2 (ru) * 2002-12-06 2009-03-10 Норсуэст Байотерапьютикс, Инк. Введение дендритных клеток, подвергнутых частичному созреванию in vitro, для лечения опухолей
US20070134273A1 (en) * 2004-02-10 2007-06-14 Francois Romagne Composition and method for the treatment of carcinoma
US8076132B2 (en) 2004-09-17 2011-12-13 Hasumi International Research Foundation Dendritic cell tumor injection (DCTI) therapy
US20060216269A1 (en) * 2004-09-17 2006-09-28 Kenichiro Hasumi Dendritic cell tumor injection (DCTI) therapy
WO2006095330A2 (en) * 2005-03-10 2006-09-14 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
WO2007001200A1 (fr) * 2005-06-23 2007-01-04 Obschestvo S Ogranichennoi Otvetsvennostyu 'rusgen' Cellules dendritiques matures chargees d'un polylysat de tumeurs, et vaccin antitumoral a base desdites cellules
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
WO2008133595A1 (en) * 2007-04-26 2008-11-06 Newbiomed Pika Pte Ltd Compositions and methods for stimulating an immune response in-vivo and in-vitro
WO2008151389A1 (en) * 2007-06-15 2008-12-18 Macfarlane Burnet Institute For Medical Research And Public Health Limited Chemically modified macromolecules
EP2072617A1 (en) * 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
CN102016007B (zh) * 2008-03-27 2019-04-19 阿斯特利亚斯生物治疗股份公司 使灵长类多能干细胞分化成为造血谱系细胞
CN107007626A (zh) * 2009-07-09 2017-08-04 蒂盖尼克斯公司 用于细胞治疗的方法和组合物
DK2534242T3 (en) * 2010-02-10 2016-07-18 Immunicum Ab Improved composition for the inhibition of tumor cell proliferation
CN102933228A (zh) * 2010-03-15 2013-02-13 宾夕法尼亚大学董事会 制备和储存活化的、成熟树突细胞的体系和方法
RU2530523C2 (ru) * 2012-03-29 2014-10-10 Олег Борисович Егоров Способ противоопухолевой иммунотерапии
RU2678083C2 (ru) * 2012-06-27 2019-01-23 Кенитиро Хасуми Терапия и способ внутриопухолевого введения цитотоксического т-лимфоцита и/или nkt-клетки с антителом против tnf и/или антителом против il-10
GB201300049D0 (en) * 2013-01-03 2013-02-20 Transimmune Ag Method for obtaining immuno-stimulatory dendritic cells
BR112016010224A2 (pt) 2013-11-05 2018-05-02 Cognate Bioservices, Inc. combinações de inibidores do ponto de verificação e produtos terapêuticos para tratar o câncer.
GB201413665D0 (en) * 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
MX2018000056A (es) * 2015-06-30 2018-05-28 Northwest Biotherapeutics Inc Celulas dendriticas optimamente activadas que inducen una respuesta inmunologica antitumoral mayor o mejorada.
WO2017048875A1 (en) * 2015-09-15 2017-03-23 Northwest Biotherapeutics, Inc Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers
KR101749165B1 (ko) * 2016-06-07 2017-06-23 충남대학교산학협력단 Rv2299c 또는 Rv2299c와 ESAT-6 융합한 단백질을 포함하는 수지상 세포의 성숙화 촉진용 조성물
WO2018160666A1 (en) * 2017-02-28 2018-09-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated dc1s and methods for their production and use
GB201711379D0 (en) * 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
CN109957548B (zh) * 2017-12-26 2022-03-18 上海尚泰生物技术有限公司 一种基因修饰的树突状细胞疫苗
GB2624871A (en) * 2022-11-29 2024-06-05 Alv B As Process for preparing a population of dendritic cells and immunotherapy using the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3649335B2 (ja) 1992-04-01 2005-05-18 ザ ロックフェラー ユニバーシティー 樹枝状細胞前駆体のインビトロ増殖の方法およびその免疫原製造への使用
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US6797488B1 (en) * 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
CN1330557A (zh) * 1998-09-15 2002-01-09 匹兹堡大学联邦系统高等教育 原位注射具有基因上增进细胞因子表达的抗原呈递细胞
EP1126023A4 (en) * 1998-10-02 2005-02-16 Mitsubishi Chem Corp METHOD FOR THE INDUCTION OF CELLULAR IMMUNITY AND CELLS WITH INDUCED CELLULAR IMMUNITY
US6649158B1 (en) * 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
BR0009772A (pt) * 1999-04-14 2002-01-08 Us Health Composições contendo imunotoxinas e agentes que inibem a maturação de células dendrìticas para induzir tolerância imune a um enxerto
US20030108527A1 (en) * 1999-12-28 2003-06-12 Tsukasa Seya Maturation-promoting agent for immature dendrtic cells
JP2002069001A (ja) * 2000-08-29 2002-03-08 Asahi Kasei Corp 樹状細胞を主成分とする細胞ワクチン
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
WO2003010292A2 (en) 2001-07-25 2003-02-06 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
BRPI0212545B8 (pt) * 2001-09-06 2021-05-25 Northwest Biotherapeutics Inc método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t
RU2348418C2 (ru) * 2002-12-06 2009-03-10 Норсуэст Байотерапьютикс, Инк. Введение дендритных клеток, подвергнутых частичному созреванию in vitro, для лечения опухолей
ATE420946T1 (de) * 2003-02-27 2009-01-15 Northwest Biotherapeutics Inc Erzeugung dendritischer zellen aus monozytischen dendritischen vorläuferzellen mit gm-csf ohne anwesenheit zusätzlicher zytokine

Also Published As

Publication number Publication date
BRPI0317064B1 (pt) 2020-11-03
KR101144196B1 (ko) 2012-05-21
JP4859169B2 (ja) 2012-01-25
CN1738619B (zh) 2012-04-18
EP1567155A4 (en) 2006-12-13
EP2260861A1 (en) 2010-12-15
EP1567155B1 (en) 2010-10-27
HK1082180A1 (en) 2006-06-02
MXPA05006042A (es) 2005-09-21
IL169002A (en) 2015-01-29
BRPI0317064B8 (pt) 2021-05-25
RU2348418C2 (ru) 2009-03-10
CA2509058A1 (en) 2004-06-24
AU2003293411A1 (en) 2004-06-30
US20060057120A1 (en) 2006-03-16
AU2003293411B2 (en) 2010-10-28
WO2004053072A2 (en) 2004-06-24
DK1567155T3 (da) 2011-02-14
JP2006510667A (ja) 2006-03-30
CN102600461B (zh) 2017-07-14
CN1738619A (zh) 2006-02-22
EP1567155A2 (en) 2005-08-31
RU2005121256A (ru) 2006-02-10
JP5707284B2 (ja) 2015-04-30
AU2011200352A1 (en) 2011-02-17
CN102600461A (zh) 2012-07-25
US20120251561A1 (en) 2012-10-04
PT1567155E (pt) 2011-01-28
ATE486125T1 (de) 2010-11-15
BR0317064A (pt) 2005-10-25
ES2354944T3 (es) 2011-03-21
WO2004053072A3 (en) 2005-06-16
DE60334725D1 (de) 2010-12-09
AU2011200352B2 (en) 2013-06-27
JP2011246493A (ja) 2011-12-08
KR20050084189A (ko) 2005-08-26

Similar Documents

Publication Publication Date Title
HK1082180A1 (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors
Libraty et al. Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy.
Okamoto et al. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation
Bilsborough et al. Mucosal CD8α+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties
Grabbe et al. Tumor antigen presentation by epidermal antigen‐presenting cells in the mouse: modulation by granulocyte‐macrophage colony‐stimulating factor, tumor necrosis factor α, and ultraviolet radiation
CA2483012A1 (en) Oligonucleotide compositions and their use for the modulation of immune responses
Salio et al. Dendritic cell maturation is induced by mycoplasma infection but not by necrotic cells
ES2113980T3 (es) Ligandos solubles para cd40.
Waltenbaugh et al. Alcohol consumption alters antigen‐specific Th1 responses: mechanisms of deficit and repair
DK0668781T3 (da) Lymfokingenterapi af cancer i kombination med tumorantigener
DK1225870T3 (da) Sammensætning og fremgangsmåde til cancerantigenimmunterapi
DE69839273D1 (de) Krebs immuntherapie mit semi-allogenen zellen
WO2002036141A3 (en) Method of enhancing lymphocyte-mediated immune responses
Mazzoccoli et al. Immune system alterations in lung cancer patients
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
MXPA04001872A (es) Modelo de exposicion a micoplasma bovis, procedimiento para administrar m. bovis y procedimientos para inducir lesiones pulmonares neumonicas.
MX2023001622A (es) Celulas dendriticas optimamente activadas que inducen una respuesta inmunologica antitumoral mayor o mejorada.
Gelfand Essential role of T lymphocytes in the development of allergen-driven airway hyperresponsiveness
YU40796A (sh) Preparati i postupci za tretiranje obolenja koja izazivaju t ćelije
Son et al. Dendritic cells pulsed with apoptotic squamous cell carcinoma have anti‐tumor effects when combined with interleukin‐2
Enioutina et al. The induction of systemic and mucosal immunity to protein vaccines delivered through skin sites exposed to UVB
Harada et al. Role of the endogenous production of interleukin 12 in immunotherapy
WO2002015915A3 (en) Method for inducing an anti-tumor and anti-cachexia immune response in mammals
Iwashita et al. Potent stimuli combined with lipopolysaccaride and IFNγ may improve immunotherapy against HCC by increasing the maturation and subsequent immune response of the dendritic cells
CA2442300A1 (en) Cd8.alpha. + lymphoid dendritic cell differentiated from human hematopoietic stem cell and a method for differentiation

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)